NGM - NGM BIOPHARMACEUTICALS INC
Close
1.55
1.550 100.000%
Share volume: 0
Last Updated: Thu 04 Apr 2024 08:16:47 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-05 | 2022-08-04 | 2022-11-03 | 2023-02-28 | 2023-05-04 | 2023-08-03 | 2023-11-02 | |
| Total revenue | 20.948 M | 8.293 M | 7.911 M | 18.181 M | 2.247 M | 1.423 M | 582.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 20.948 M | 8.293 M | 7.911 M | 18.181 M | 2.247 M | 1.423 M | 582.000 K | |
| -60.41% | -4.61% | 129.82% | -87.64% | -36.67% | -59.10% | |||
| Operating expenses | 53.529 M | 55.360 M | 56.215 M | 56.478 M | 52.441 M | 41.998 M | 31.613 M | |
| Selling general and admin | 10.723 M | 9.927 M | 10.109 M | 9.756 M | 11.584 M | 9.647 M | 8.671 M | |
| Research and development | 42.806 M | 45.433 M | 46.106 M | 46.722 M | 40.857 M | 32.351 M | 22.942 M | |
| Total expenses | 53.529 M | 55.360 M | 56.215 M | 56.478 M | 52.441 M | 41.998 M | 31.613 M | |
| 3.42% | 1.54% | 0.47% | -7.15% | -19.91% | -24.73% | |||
| Operating income | -32.581 M | -47.067 M | -48.304 M | -38.297 M | -50.194 M | -40.575 M | -31.031 M | |
| Ebit | -32.581 M | -47.067 M | -48.304 M | -38.297 M | -50.194 M | -40.575 M | -31.031 M | |
| Pretax income | -32.450 M | -46.519 M | -47.261 M | -36.437 M | -47.647 M | -38.261 M | -28.797 M | |
| 43.36% | 1.60% | -22.90% | 30.77% | -19.70% | -24.74% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -32.450 M | -46.519 M | -47.261 M | -36.437 M | -47.647 M | -38.261 M | -28.797 M | |
| -43.36% | -1.60% | 22.90% | -30.77% | 19.70% | 24.74% | |||
| Net income | -32.450 M | -46.519 M | -47.261 M | -36.437 M | -47.647 M | -38.261 M | -28.797 M | |
| -43.36% | -1.60% | 22.90% | -30.77% | 19.70% | 24.74% |